Redeye comments on Truecaller’s Q4 2024 report, which exceeded expectations on all levels.
Net sales SEK 202m, +7% vs ABGSCe and Factset cons.
Redeye provides an update following Nitro Games’ Q4 2024 report, which came in slightly better than ...
Redeye updates its estimates and fair value range following Arise’s Q4 2024 report, which marked the...
Net sales were in line with our expectation, but clean EBITA was a bit weaker than we had forecast f...
We lower our 2025-26 sales estimates by 4%, mainly driven by Germany.
Redeye endorses today’s news that AlzeCure has received a EUR2.
Another quarter of y-o-y margin improvement Margin-driven EBITA upgrades of 6-4% for '25e-'26e Share...
Obducat (”Obducat” eller ”Bolaget”) publicerade den 14 februari 2025 Bolagets delårsrapport för det ...
Redeye strengthens its positive view of Formpipe following the Q4 report.
Aspo’s Q4 earnings came in a bit soft relative to estimates, but the midpoint of FY’25 comparable EB...
Redeye shares its preview of BONESUPPORT’s Q4 2024 results, due February 25.
Minor estimate revisions Delivery of IC2000 within one quarter of order 3.
För det kommande året tror Analysguiden på ytterligare några räntesänkningar, vilket kommer att få e...
Redeye comments on Nitro Games' Q4 2024 report, which came in slightly ahead of our estimates both o...
Redeye returns with a more in-depth take on Sedana Medical’s Q4 report.
Redeye updates its view on Genovis following the company's year-end report.
Doro delivered another report with solid gross and operating margins.
Aspo reported a weak Q4 that was affected by low industrial activity and low spot prices in ESL, whe...
Redeye argues that BeammWave has shifted to a new phase with three customers representing most of th...
